RecruitingPhase 2NCT07536789

Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma

Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma: A Single-arm, Multi-cohort, Phase 2 Trial

Sponsor

Fudan University

Enrollment

40 participants

Start Date

Apr 17, 2026

Study Type

INTERVENTIONAL

Conditions

Hepato Cellular Carcinoma (HCC)

Summary

This study will evaluate the efficacy and safety of Becotatug vedotin, MRG003, in previously treated advanced hepatocellular carcinoma (HCC).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called MRG003 for people with hepato cellular carcinoma (hcc). The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMRG003

MRG003 will be administered by IV, 2.3 mg/kg on day 1 of each 21 day cycle until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.

Locations(1)

Zhongshan Hospital, Fudan University

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07536789

Related Trials

The Impact of Anaesthesia and Sedation on Inflammation and NETosis in Hepatocellular Carcinoma Ablation

NCT076578971 location

Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC)

NCT0699065919 locations

Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab

NCT072761001 location

SHIELD: Sorafenib Hand-foot Syndrome Inhibition With Pre-Emptive Local Delivery of Topical Indomethacin

NCT075605661 location

A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma

NCT073280091 location